{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T20:10:19Z","timestamp":1732479019180,"version":"3.28.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,24]]},"DOI":"10.7759\/cureus.74357","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T19:28:09Z","timestamp":1732476489000},"source":"Crossref","is-referenced-by-count":0,"title":["Triple Therapy IDP-126 Gel for Acne Treatment: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Kennedy","family":"Sparling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakshita","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anngela C","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria G","family":"Farley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos T","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M, et al.. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012, 380:2163-96. 10.1016\/S0140-6736(12)61729-2","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1997.tb01126.x","article-title":"Descriptive epidemiology of acne vulgaris in the community","volume":"38","author":"Stathakis V","year":"1997","unstructured":"Stathakis V, Kilkenny M, Marks R. Descriptive epidemiology of acne vulgaris in the community. Australas J Dermatol. 1997, 38:115-23. 10.1111\/j.1440-0960.1997.tb01126.x","journal-title":"Australas J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms7050128","article-title":"Propionibacterium acnes and acne vulgaris: new insights from the integration of population genetic, multi-omic, biochemical and host-microbe studies","volume":"7","author":"McLaughlin J","year":"2019","unstructured":"McLaughlin J, Watterson S, Layton AM, Bjourson AJ, Barnard E, McDowell A. Propionibacterium acnes and acne vulgaris: new insights from the integration of population genetic, multi-omic, biochemical and host-microbe studies. Microorganisms. 2019, 7:128. 10.3390\/microorganisms7050128","journal-title":"Microorganisms"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(08)80076-x","article-title":"Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990","volume":"24","author":"Pochi PE","year":"1991","unstructured":"Pochi PE, Shalita AR, Strauss JS, et al.. Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990. J Am Acad Dermatol. 1991, 24:495-500. 10.1016\/s0190-9622(08)80076-x","journal-title":"J Am Acad Dermatol"},{"key":"ref5","article-title":"Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial","volume":"86","author":"Yentzer BA","year":"2010","unstructured":"Yentzer BA, Ade RA, Fountain JM, Clark AR, Taylor SL, Fleischer AB Jr, Feldman SR. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010, 86:103-8.","journal-title":"Cutis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2995","article-title":"Comparative efficacy of pharmacological treatments for acne vulgaris: a network meta-analysis of 221 randomized controlled trials","volume":"21","author":"Huang CY","year":"2023","unstructured":"Huang CY, Chang IJ, Bolick N, et al.. Comparative efficacy of pharmacological treatments for acne vulgaris: a network meta-analysis of 221 randomized controlled trials. Ann Fam Med. 2023, 21:358-69. 10.1370\/afm.2995","journal-title":"Ann Fam Med"},{"key":"ref7","unstructured":"FDA approves CabtreoTM (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel for the treatment of acne vulgaris in patients twelve years of age and older. (2023). https.\/\/ir.bauschhealth.com\/news-releases\/2023\/10-20-2023."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00650-3","article-title":"Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: a randomized phase ii study of the first triple-combination drug","volume":"23","author":"Stein Gold L","year":"2022","unstructured":"Stein Gold L, Baldwin H, Kircik LH, et al.. Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: a randomized phase ii study of the first triple-combination drug. Am J Clin Dermatol. 2022, 23:93-104. 10.1007\/s40257-021-00650-3","journal-title":"Am J Clin Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-00417-3","article-title":"Acne, the skin microbiome, and antibiotic treatment","volume":"20","author":"Xu H","year":"2019","unstructured":"Xu H, Li H. Acne, the skin microbiome, and antibiotic treatment. Am J Clin Dermatol. 2019, 20:335-44. 10.1007\/s40257-018-00417-3","journal-title":"Am J Clin Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.069","article-title":"Clindamycin phosphate 1.2%\/adapalene 0.15%\/benzoyl peroxide 3.1% gel for moderate-to-severe acne: efficacy and safety results from two randomized phase 3 trials","volume":"89","author":"Stein Gold L","year":"2023","unstructured":"Stein Gold L, Lain E, Del Rosso JQ, et al.. Clindamycin phosphate 1.2%\/adapalene 0.15%\/benzoyl peroxide 3.1% gel for moderate-to-severe acne: efficacy and safety results from two randomized phase 3 trials. J Am Acad Dermatol. 2023, 89:927-35. 10.1016\/j.jaad.2022.08.069","journal-title":"J Am Acad Dermatol"},{"key":"ref11","unstructured":"Study comparing the safety and efficacy of IDP-120 gel and IDP-120 vehicle gel in the treatment of acne vulgaris. (2023). https.\/\/clinicaltrials.gov\/study\/NCT03664739."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi SA","year":"2024","unstructured":"Nejadghaderi SA, Balibegloo M, Rezaei N. The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons. Health Sci Rep. 2024, 7:e2165. 10.1002\/hsr2.2165","journal-title":"Health Sci Rep"},{"key":"ref13","unstructured":"Robvis (visualization tool). https.\/\/www.riskofbias.info\/welcome\/robvis-visualization-tool."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7927","article-title":"Benefit of topical combination therapy for acne: analyzing effect size using number needed to treat","volume":"23","author":"Feldman SR","year":"2024","unstructured":"Feldman SR, Han G, Callender VD, et al.. Benefit of topical combination therapy for acne: analyzing effect size using number needed to treat. J Drugs Dermatol. 2024, 23:42-9. 10.36849\/JDD.7927","journal-title":"J Drugs Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2220446","article-title":"Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%\/benzoyl peroxide 3.1%\/adapalene 0.15% gel from three clinical trials","volume":"34","author":"Draelos ZD","year":"2023","unstructured":"Draelos ZD, Tanghetti EA, Kircik LH, Bhatia N, Zeichner JA, Sugarman JL, Stein Gold L. Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%\/benzoyl peroxide 3.1%\/adapalene 0.15% gel from three clinical trials. J Dermatolog Treat. 2023, 34:2220446. 10.1080\/09546634.2023.2220446","journal-title":"J Dermatolog Treat"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7812","article-title":"Post-hoc exploratory pooled analysis of the impact of IDP-126 gel on QoL in moderate-to-severe acne","volume":"22","author":"Gold LS","year":"2023","unstructured":"Gold LS, Harding G, Borroto D, et al.. Post-hoc exploratory pooled analysis of the impact of IDP-126 gel on QoL in moderate-to-severe acne. J Drugs Dermatol. 2023, 22:1033-9. 10.36849\/JDD.7812","journal-title":"J Drugs Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/312021-triple-therapy-idp-126-gel-for-acne-treatment-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T19:28:11Z","timestamp":1732476491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/312021-triple-therapy-idp-126-gel-for-acne-treatment-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,24]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.74357","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2024,11,24]]}}}